REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) has scheduled a conference call for Wednesday, November 6, at 4:30 p.m. ET to present its Q3 2024 financial results and recent operational highlights. The call will include a question-and-answer session for analysts, and participants are advised to join 15 minutes before the start time. A webcast replay will be available on the company's investor website approximately two hours after the call ends.

News Market Reaction – RGNX

-2.43%

1 alert

-2.43% News Effect

On the day this news was published, RGNX declined 2.43%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

10/30/2024 - 07:05 AM

ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024, and recent operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma^® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-6-to-discuss-third-quarter-2024-financial-results-and-recent-operational-highlights-302291244.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO (RGNX) reporting Q3 2024 earnings?

REGENXBIO (RGNX) will report its Q3 2024 earnings on Wednesday, November 6, at 4:30 p.m. ET.

How can I access REGENXBIO's (RGNX) Q3 2024 earnings call?

Listeners can access the earnings call through a webcast link provided by the company, and analysts can participate in the Q&A session through a separate dedicated link.